Giant-cell tumor of bone : treatment options and role of denosumab

Discusses the role of denosumab, a monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), in modifying the pathogenesis of giant-cell tumor of bone (GCTB), and the evolving management of GCTB with the introduction of denosumab. Source: National Library of New Zealand Te...

Full description

Saved in:
Bibliographic Details
Published in:Biologics 2015-01, Vol.9 (default), p.69-74
Main Authors: Singh, Arun S, Chawla, Neal S, Chawla, Sant P
Format: Article
Language:English
Subjects:
Analysis
Bone cancer
Bones
Cancer therapies
Care and treatment
Complications and side effects
Drug approval
Giant cell tumors
Immunotherapy
Influence
Metastasis
Monoclonal antibodies
Mutation
Pathogenesis
Radiation therapy
Review
Sarcoma
Targeted cancer therapy
Therapeutic use
Treatment
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Discusses the role of denosumab, a monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), in modifying the pathogenesis of giant-cell tumor of bone (GCTB), and the evolving management of GCTB with the introduction of denosumab. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.
ISSN:1177-5475
1177-5491
1177-5491
DOI:10.2147/btt.s57359